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CORRESPONDENCE
Shielding blood donors from 
harm
To the Editor: Eric Klug’s letter in the June SAMJ[1] is 
particularly topical, as haemovigilance programmes 
have extended to include donor health in recent years. 
Considerable attention has focused on the effects of 
regular blood donation on iron stores, and consequent 
risks of iron depletion and iron deficiency anaemia. 
There is little doubt that frequent blood donation may 
result in reduced iron stores. It is also important to note 
that haemoglobin (Hb) levels may remain relatively 
normal in spite of reduced iron stores, although changes 
in the red cell indices may be helpful in suggesting iron 
deficiency. Females of childbearing age are most at risk 
of iron depletion due to menstruation, pregnancy, a 
lower body mass and lower oral iron intake.
There are two blood transfusion services in South 
Africa (SA). The South African National Blood Service 
(SANBS) covers the whole of SA with the exception of 
the Western Cape Province, which is serviced by the 
Western Province Blood Transfusion Service (WPBTS). 
The two services follow similar principles with regard to 
blood donor screening.
The SANBS screens Hb levels of all donors at each 
donation using the copper sulphate specific gravity 
method. If the donor’s blood fails on this test, a HemoCue 
reading (a bedside Hb monitor) is done. The cut-off for 
all SANBS donors is an Hb level of 12.5 g/dl. If the donor 
fails the HemoCue test, they are given a letter of referral 
to their healthcare practitioner noting whether this is a 
first or repeat donation, and the number of donations. 
Dietary advice is offered to all donors, and in line with 
best practice, iron supplementation, where available, 
is given to repeat female donors of childbearing age. 
Female donors with Hb levels of 11.1 - 12.4 g/dl and 
male donors with levels of 11.4 - 12.4 g/dl are deferred 
from donating blood for 3 months. Female donors with 
an Hb level of 10.5 - 11.0 g/dl are deferred for 6 months, 
and those with Hb levels <10.5 g/dl for 12 months. Male 
donors with an Hb level of 10.5 - 11.3 g/dl are deferred 
from donating blood for 6 months and those with levels 
<10.5 g/dl for 12 months.
The WPBTS screens all donors at each donation using 
the HemoCue test. The Hb cut-off level for allowing 
donors to donate is 12.5 g/dl for females and 13.5 g/
dl for males. Regular donors failing to meet the cut-
off levels have a sample taken for a full blood count 
(FBC). No matter what the results are, these donors 
later receive a letter with their FBC results, reflecting 
one of the following possibilities: (i) failure of Hb 
screening test confirmed, but no evidence of anaemia 
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or iron deficiency; (ii) failure of Hb screening test and evidence of 
anaemia or iron deficiency; or (iii) false failure of Hb screening test. 
Where indicated, donors are advised to see their own clinicians for 
further investigation and/or treatment. As with the SANBS, routine 
measurement of ferritin levels is not performed. The WPBTS recently 
introduced an oral iron replacement programme. A short course (30 
tablets) of iron sulphate tablets is offered to those donors most at 
risk – currently female donors up to age 50 years who have donated 
two or more times in the preceding 12 months. This short course 
is intended only to replace the iron lost through donation, and 
not as a treatment for iron deficiency or iron deficiency anaemia. 
Accompanying information is supplied to explain the programme 
as well as to warn of side-effects. Research will be conducted over 
the next 2 - 3 years in order to determine whether ferritin levels are 
maintained in those donors who receive iron replacement v. those 
who do not.
There are limited strategies aimed at reducing the risks of iron 
depletion in blood donors, each with its own challenges. The 
frequency of donation can be reduced to three or four donations 
per year. However, this would require a significant increase in the 
number of active blood donors to ensure that blood stocks are not 
compromised. Oral iron replacement programmes can be instituted; 
these are relatively inexpensive (particularly if iron sulphate is used), 
but the side-effects of oral iron are significant for some patients and 
compliance is limited – in a pilot study carried out by the WPBTS, 
compliance was measured at 70%. Moreover, iron replacement 
programmes are not without risks, including the potential masking 
of more sinister causes of iron deficiency. Finally, ferritin levels (the 
most robust indicator of iron stores) can be measured. As there is 
no bedside ferritin test, screening would not be in real time. The 
costs of ferritin screening would need to be recovered (as both blood 
services are non-profit organisations based on financial models of 
cost recovery), and the price of blood would rise. 
The blood transfusion services in South Africa benchmark at an 
international level to ensure blood safety by adopting guidelines put 
in place by the World Health Organization and the International 
Haemovigilance Network. Our haemovigilance programme, in addi-
tion to monitoring the safety of the transfusion chain, now includes 
donor vigilance and monitoring of international trends to minimise 
harm to donors. As such, the SANBS has embarked on a study of its 
donors in which an FBC, iron studies and ferritin levels will be done 
on a cohort of donors nationally; a sample of WPBTS donors will also 
be included. It is hoped that this will give a baseline for SA donors 
(rather than relying only on data from international studies). Using 
this analysis, going forward, interventions regarding frequency of 
donation, iron supplementation for certain donor groups and a cost-
effective plan for ferritin monitoring can be established.
Blood donors should be encouraged always to inform their treating 
clinicians that they are blood donors, and both services encourage 
this by way of a letter. In addition, both services will explore other 
avenues to inform blood donors of potential risks of donating, taking 
care not to deter donors and to ensure that the blood supply is not 
compromised.
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